ABPA
9
4
4
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
11.1%
1 terminated out of 9 trials
50.0%
-36.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (9)
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
Allergic Bronchopulmonary Aspergillosis Prescreening Study
Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis